371 related articles for article (PubMed ID: 18085385)
1. CKD-MBD: impact on management of kidney disease.
Ogata H; Koiwa F; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
[TBL] [Abstract][Full Text] [Related]
2. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
4. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
5. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Uemura K; Kakuta T
Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease.
Hu P; Xuan Q; Hu B; Lu L; Wang J; Qin YH
Int J Biol Sci; 2012; 8(5):663-71. PubMed ID: 22606047
[TBL] [Abstract][Full Text] [Related]
7. [Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Hamano T
Clin Calcium; 2012 Jul; 22(7):1043-9. PubMed ID: 22750937
[TBL] [Abstract][Full Text] [Related]
8. [Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Mizobuchi M; Nakazawa A; Akizawa T
Clin Calcium; 2011 Dec; 21(12):159-66. PubMed ID: 22133835
[TBL] [Abstract][Full Text] [Related]
9. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].
Taniguchi M
Clin Calcium; 2010 Jul; 20(7):1078-87. PubMed ID: 20585187
[TBL] [Abstract][Full Text] [Related]
10. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
Koiwa F; Maruta Y
Clin Calcium; 2010 Jul; 20(7):1089-95. PubMed ID: 20585188
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet].
Bonny O; Burnier M
Rev Med Suisse; 2008 Mar; 4(147):589-92, 594-5. PubMed ID: 18402017
[TBL] [Abstract][Full Text] [Related]
12. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
13. [Management of secondary hyperparathyroidism].
Cunningham J
Clin Calcium; 2005 Sep; 15 Suppl 1():217-24. PubMed ID: 16279027
[No Abstract] [Full Text] [Related]
14. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
15. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Yokoyama K
Clin Calcium; 2010 Jul; 20(7):1012-20. PubMed ID: 20585179
[TBL] [Abstract][Full Text] [Related]
16. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
17. [New Developments in CKD-MBD. New aspects in phosphate binders].
Yokoyama K
Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
[TBL] [Abstract][Full Text] [Related]
18. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
Nakai K; Komaba H; Fukagawa M
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
[TBL] [Abstract][Full Text] [Related]
19. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Hanafusa N
Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Ginsberg C; Zelnick LR; Block GA; Chertow GM; Chonchol M; Hoofnagle A; Kestenbaum B; de Boer IH
Nephrol Dial Transplant; 2020 Apr; 35(4):616-623. PubMed ID: 32160298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
